Atara Biotherapeutics (NASDAQ:ATRA) Share Price Crosses Below 50 Day Moving Average of $0.73

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.73 and traded as low as $0.68. Atara Biotherapeutics shares last traded at $0.71, with a volume of 832,144 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 5th.

Atara Biotherapeutics Price Performance

The firm’s 50 day moving average price is $0.72 and its 200-day moving average price is $0.80. The firm has a market cap of $78.90 million, a price-to-earnings ratio of -0.25 and a beta of 0.69.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.05. Atara Biotherapeutics had a negative net margin of 3,220.88% and a negative return on equity of 783.31%. The business had revenue of $4.25 million during the quarter, compared to analyst estimates of $2.45 million. Analysts expect that Atara Biotherapeutics, Inc. will post -1.3 EPS for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its stake in Atara Biotherapeutics by 334.0% in the 1st quarter. Tower Research Capital LLC TRC now owns 9,041 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 6,958 shares in the last quarter. Ergoteles LLC bought a new position in shares of Atara Biotherapeutics during the second quarter valued at $33,000. Vontobel Holding Ltd. acquired a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at $41,000. Point72 Middle East FZE bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth about $41,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth about $45,000. 70.90% of the stock is owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.